Pharmaceuticals December 5, 2024

MariTide’s Weight Loss Milestone December 5, 2024

The red hot weight loss segment just got even hotter, as the Phase 2 trial of Amgen’s maridebart cafraglutide (MariTide) yielded exceptional body mass reductions among people with obesity and T2D, propelling the pharma giant closer to FDA approval. Building on this earlier success, Amgen’s new Phase 2 trial lasted 52 weeks and enrolled patients […]

Pharmaceuticals December 2, 2024

Winrevair’s Big PAH Win December 2, 2024

Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. The ZENITH trial randomized 172 patients to either receive Winrevair and background PAH therapy, or placebo and PAH therapy. […]

Cholesterol Reduction November 25, 2024

Muvalaplin Aces Phase 2 Lp(a) Test November 25, 2024

Impressive results from the Phase 2 KRAKEN trial presented at the AHA 2024 Scientific Sessions showed that Eli Lilly’s muvalaplin greatly reduces Lp(a) blood levels, adding an attractive oral option to its Lp(a) pipeline. By the study’s 12-week endpoint, patients experienced significant reductions in blood Lp(a) when taking oral muvalaplin across three different doses, compared […]

Cardiology November 21, 2024

Ablation or Antiarrhythmics for Ventricular Tachycardia? November 21, 2024

Late-breaking results from the VANISH2 trial presented at AHA 2024 showed that catheter ablation might be a better first-line treatment than antiarrhythmic drugs for ventricular tachycardia patients with ischemic cardiomyopathy. To address this uncertainty, the VANISH2 trial recruited 416 patients with clinically significant VT, ischemic cardiomyopathy, previous MI, and an ICD, randomizing them to receive […]

More Stories

Pharmaceuticals November 18, 2024

Tirzepatide’s Prediabetes Triumph November 18, 2024

Eli Lilly’s GLP-1 tirzepatide has triumphed yet again, as the full SURMOUNT-1 trial showed that the drug kept nearly 99% of prediabetic patients diabetes-free over 3 years, while improving cardiometabolic metrics. In the final results from the three-year SURMOUNT-1 trial, tirzepatide lowered the risk of progression to Type 2 diabetes by 94% versus placebo in […]

Surgeries & Interventions November 14, 2024

Forgotten IVC Filters Aren’t SAFE November 14, 2024

Troubling results from the SAFE-IVC study revealed that just one in six patients gets their inferior vena cava filters removed, despite clear guidelines calling for IVC filter removal as early as possible. Out of SAFE-IVC’s roughly 270k Medicare beneficiaries, only 15% had their IVC filters retrieved within 1.2 years of insertion. Patients who didn’t have […]

Surgeries & Interventions November 11, 2024

LimFlow Limits Limb-Threatening Ischemia November 11, 2024

Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia (CLTI).  LimFlow remained effective at two years, with a 65% limb salvage rate that was just 4% below the PROMISE II trial’s one year […]

Atrial Fibrillation November 7, 2024

Boston Scientific Bolsters AFib Mapping with Cortex Acquisition November 7, 2024

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. for an undisclosed sum. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases. […]

Surgeries & Interventions November 4, 2024

TCT 2024’s Top TAVR Studies November 4, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Out of all these TAVR studies, the four that could have the greatest clinical impact focused on interventional timing and the risk of comorbidities and procedural complications. The EARLY […]

Cardiology October 31, 2024

The 40 Best Cardiology Newsletters, Websites, and Influencers to Follow in 2024 October 31, 2024

We’re dedicating today’s top story to the people and publications that we rely on to find the most interesting cardiology stories from across the web. Assuming that you already subscribe to Cardiac Wire, these are the 40 other newsletters, websites, and social media stars to follow if you want to keep up with the latest […]

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!